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Abstract 
Multiple reports now describe changes to the DNA methylome in rheumatoid arthritis 
and in many cases have analyzed methylation in mixed cell populations from whole 
blood. However, these approaches may preclude the identification of cell type-specific 
methylation, which may subsequently bias identification of disease-specific changes. To 
address this possibility, we conducted genome-wide DNA methylation profiling using 
HumanMethylation450 BeadChips to identify differences within matched pairs of T-
lymphocytes and B-lymphocytes isolated from the peripheral blood of 10 healthy 
females. Array data were processed and differential methylation identified using 
NIMBL software. Validation of array data was performed by bisulfite Pyrosequencing. 
Genome-wide DNA methylation was initially determined by analysis of LINE-1 
sequences and was higher in B-lymphocytes than matched T-lymphocytes (69.8 vs. 
65.2%, p ≤ 0.01). Pairwise analysis identified 679 CpGs, representing 250 genes, which 
were differentially methylated between T-lymphocytes and B-lymphocytes. The 
majority of sites (76.6%) were hypermethylated in B-lymphocytes. Pyrosequencing of 
selected candidates confirmed the array data in all cases. Hierarchical clustering 
revealed perfect segregation of samples into two distinct clusters based on cell type. 
Differentially methylated genes showed enrichment for biological functions/pathways 
associated with leukocytes and T-lymphocytes. Our work for the first time shows that 
T-lymphocytes and B-lymphocytes possess intrinsic differences in DNA methylation 
within a restricted set of functionally-related genes. These data provide a foundation for 
investigating DNA methylation in diseases in which these cell types play important and 
distinct roles.  
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Introduction 
DNA methylation, one of several prototypical epigenetic mechanisms, regulates gene 
expression without imposing alterations to the underlying nucleotide sequence. It is 
important in a variety of fundamental biological processes1-3 and in humans occurs 
almost exclusively on cytosines in the context of cytosine-guanine dinucleotides 
(CpGs). These dinucleotides are found to cluster at high density in regions of DNA 
termed CpG islands, and are often associated with gene promoters.4,5 With particular 
exceptions, they are typically not methylated in transcriptionally competent genes.6 
Conversely, methylation of promoter-associated CpGs is frequently associated with 
transcriptional repression and gene silencing.6 
 
There is now compelling evidence that aberrant DNA methylation is involved in a 
variety of human diseases, most notably in cancer etiology and, more recently, a 
growing spectrum of autoimmune disorders that include rheumatoid arthritis (RA). 
Distinct leukocyte populations, particularly lymphocytes and their subsets, play a 
pivotal role in RA pathogenesis, driving autoimmunity and chronic inflammation. 
Levels of global DNA methylation have been found to be altered in lymphocytes and 
peripheral blood mononuclear cells from patients with RA.7-9 Moreover, others have 
also reported aberrant methylation in RA, but in these cases have examined individual 
genes and using DNA samples derived from whole blood or the mononuclear cell 
fraction.10-15 Although these studies have identified genes potentially involved in RA 
pathogenesis, they are not able to consider the distinct roles of individual leukocyte 
populations. Furthermore, analysis of mixed cell samples may preclude the 
identification of important cell type-specific and disease-specific methylation changes 
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due to the inherent cellular heterogeneity. Indeed, this view is supported by recent 
evidence indicating that leukocyte heterogeneity may be a confounder for DNA 
methylation analyses on whole blood,16 and that individual leukocyte populations show 
evidence of differences in methylation.17 In this context, a recent genome-wide study in 
RA by Liu et al18 utilized a statistical algorithm to estimate and adjust for blood 
leukocyte proportions, concluding this to be a critical step for downstream bioinformatic 
analyses.  
 
It is clear therefore that the examination of individual leukocyte populations that drive 
disease is an important step towards better understanding the role of DNA methylation 
in conditions such as RA. A prerequisite to this goal must first be to define the intrinsic 
differences in methylation between individual leukocyte populations. In the current 
work, we have taken a stringent methodological approach to address these issues by 
defining genome-wide DNA methylation profiles in highly purified matched pairs of T-
lymphocytes and B-lymphocytes isolated from the blood of healthy individuals. 
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Results 
450K array technical validation 
Genome-wide DNA methylation at 485,577 CpG sites (99% of RefSeq genes), was 
examined using the HumanMethylation450 BeadChip  (henceforth referred to as “450K 
array” or “array”; Illumina Inc.) to identify differences in methylation between matched 
pairs of T-lymphocytes and B-lymphocytes isolated from the blood of ten healthy 
females. We first performed a technical validation of the array data using an 
independent technique, in this case, sodium bisulfite Pyrosequencing. To this end, five 
CpGs were selected at random, from three separate genes (AMN, HMOX2 and 
PM20D1), which represented the spectrum of possible array β-values (0 to 1). These 
sites, which were analyzed in paired samples from seven of the ten individuals chosen 
randomly, revealed excellent correlation between array β-values and methylation 
determined by Pyrosequencing (Spearman’s r = 0.952, p < 0.00001) (Figure 1). Since 
the correlation was apparent across the spectrum of β-values it is unlikely to be 
consequent to the dominance of extreme values.19 
 
Assessment of global DNA methylation 
Methylation of the LINE-1 retrotransposon is frequently used as a surrogate measure of 
global DNA methylation levels.20,21 Using sodium bisulfite Pyrosequencing we 
quantified methylation across 3 adjacent CpG sites within the LINE-1 sequence. Mean 
LINE-1 methylation was similar in each individual for each specific cell type; however, 
a subtle difference between the cell types was observed, 65.2% in T-lymphocytes and 
69.8% in B-lymphocytes (Figure 2). Similar levels of methylation have been reported 
for peripheral blood leukocytes.22 We noted that LINE-1 methylation was consistently 
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higher in B-lymphocytes for each of the three CpGs inspected. Although these 
differences were subtle they were statistically significant at individual sites and also 
collectively (p ≤ 0.01, Wilcoxon Signed Rank Test; Figure 2). A more gene-focused 
assessment of global methylation by calculating the average β-value across all array 
CpGs revealed no significant difference between the cell types (β = 0.562 and 0.558 in 
T-lymphocytes and B-lymphocytes, respectively, p > 0.2).  
 
A restricted set of differentially methylated CpGs distinguish T-lymphocytes and 
B-lymphocytes 
After initial array processing (described in the Methods), the remaining dataset 
comprised 484,616 CpGs. For robust identification of CpG loci displaying differential 
methylation between the two cell types, we first performed a series of filtering steps in 
which only those CpGs meeting stringent criteria were retained. The filtering criteria 
and number of CpGs remaining at each of the steps are presented in Figure 3. As a first 
step to improve the power of subsequent statistics, non-variable sites (CpGs for which 
β-values were either ≤ 0.2, or ≥ 0.8, in all 20 samples) were removed, an approach we 
and others have previously employed.23-25 For initial identification of CpGs showing a 
difference in methylation, we calculated the difference in β-value between B-
lymphocytes and T-lymphocytes for each of the ten paired samples. We next calculated 
the mean β-value difference and retained only those CpGs with a mean difference ≥ 0.2 
(step 2; Figure 3). Implementation of the subsequent steps resulted in the identification 
of 679 gene-associated CpGs displaying significant differences in methylation between 
T-lymphocytes and B-lymphocytes from the ten healthy individuals examined. 
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Hierarchical clustering and validation of candidate CpGs 
We next used hierarchical clustering to establish whether the β-value methylation 
profile for the 679 CpGs identified above was able to distinguish between the two cell 
types across the ten individuals. As presented in the heatmap and dendrograms in 
Figure 4, a perfect dichotomy was observed, with T-lymphocyte and B-lymphocyte 
samples segregating into two distinct clusters (indicated in the heatmap by green and 
red bars, respectively). Moreover, we observed this dichotomy when clustering was 
performed on the number of CpGs identified at each successive stage of the filtering 
process, from step 3 onward and identifying in this case 2,306 statistically significant 
CpGs (Supplementary Figure 1). The data therefore clearly show that the observed 
differences in methylation are highly consistent between the T- and B-lymphocytes in 
each of the ten individuals examined. 
 
Closer inspection of the 679 CpGs revealed that the majority (520 CpGs; 76.6%) 
showed higher methylation in B-lymphocytes (summary details are provided in Table 
1). The observed differences in mean β-value were in many cases pronounced 
(maximum difference of 0.86) and approximately half of the CpGs identified 
demonstrated a β-value difference of at least 0.5 (326; 48.0%) and/or were associated 
with a bona fide CpG island (326; 48.0%).26 In total, 250 genes were represented by the 
679 CpGs, with a maximum of 18 CpGs in any one gene (a complete list of CpGs/genes 
and associated β-values is provided in Supplementary Table 1). Table 2 identifies the 
20 genes displaying the largest methylation differences between the cell types (top 10 
hypermethylated genes in each cell type). Of particular note, numerous genes showing 
high methylation in B-lymphocytes and low methylation in T-lymphocytes were those 
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with known T-lymphocyte-specific expression/function, such as the CD3D and CD3G 
genes (subunits of the CD3 T-cell co-receptor). 
 
For independent validation of the candidate genes identified in our genome-wide 
approach, we selected eight which showed large methylation differences between the 
cell types and which also contained at least 2 differentially methylated CpGs that could 
be sequenced simultaneously; four genes that were hypermethylated in B-lymphocytes 
(CD3G/D, DENND2D, GIMAP7 and PITPNC1) and four that were hypermethylated in 
T-lymphocytes (CLPTM1L, DDAH2, RNH1 and SLC7A5). Validation was performed 
by sodium bisulfite Pyrosequencing (assay details are provided in Supplementary 
Table 2). Figure 5 displays data for one representative CpG from each gene examined. 
In each case, the large statistically significant differences observed between the cell 
types by array β-values were accurately replicated by Pyrosequencing (p < 0.01 for each 
CpG/gene). This was also true for each of the CpGs analyzed in each gene, as 
exemplified by the multiple CpGs in RNH1 and PITPNC1 (p < 0.01; Figure 6). 
Validation across these eight candidate genes reinforces the robustness of the array data 
and our approach to identify sites differentially methylated between T-lymphocytes and 
B-lymphocytes. 
 
Differentially methylated genes show enrichment for immune and leukocyte-
specific characteristics. 
To explore the functional characteristics of genes identified as differentially methylated 
between T-lymphocytes and B-lymphocytes, we examined gene ontologies and 
biological pathways using the online software DAVID (Database for Annotation, 
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Visualization and Integrated Discovery).27,28 Results from these analyses are provided in 
Supplementary Tables 3-5. Analysis of the 250 candidate genes revealed significant 
enrichment for multiple ontology terms (Supplementary Table 3). Thirty-two terms 
remained significant following adjustment for multiple comparisons and, of note, half of 
these (16/32) specifically related to ‘T-cell’, ‘Lymphocyte’ or ‘Leukocyte’ categories. 
Similar results identifying T-lymphocyte, leukocyte and immune related categories were 
obtained when we performed clustering on annotation terms (for example ‘T-cell 
receptor complex’ and ‘T-cell activation’; Supplementary Table 4), and also when we 
interrogated the gene set for enrichment of biological pathways (for example ‘T-cell 
receptor signaling pathway’ and ‘T helper cell surface molecules’; Supplementary 
Table 5). Genes displaying disparate methylation between the cell types are thus 
enriched for lymphocyte-related functions. 
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Discussion 
DNA methylation represents one of several principal targets for epigenetic change and 
acts in concert with other epigenetic modifications to regulate gene expression. A 
burgeoning literature describes these types of change in multiple diseases, including 
those with an autoimmune component such as RA, in which leukocytes are known to 
play a pivotal role. The majority of previous studies examining methylation in 
leukocytes from RA patients have employed DNA extracted from whole blood or the 
mononuclear cell fraction.7-15,18 However, in these cases cellular heterogeneity may be a 
confounding factor. To determine if intrinsic differences in methylation are a feature of 
individual leukocyte populations, we compared genome-wide DNA methylation profiles 
in matched pairs of T-lymphocytes and B-lymphocytes isolated from the blood of 
healthy individuals. Through this approach, our unequivocal observation is that a 
restricted set of CpGs in functionally-related genes show differential methylation 
between T-lymphocytes and B-lymphocytes, and define a DNA methylation signature 
that accurately distinguishes the two lymphocyte types. 
 
We identified a set of 679 gene-associated CpGs, representing 250 unique genes, which 
displayed altered methylation between T-lymphocytes and B-lymphocytes. For many of 
these sites striking differences in methylation were observed (β-value differences up to 
0.864), resulting in the perfect segregation of T- and B-lymphocytes into two distinct 
clusters. In common with other tissues/cell types, the majority of CpG islands in T-
lymphocytes and B-lymphocytes are unmethylated.34,35 There is also evidence from a 
variety of different tissues and cell types, including leukocytes, that some CpG islands 
show tissue-specific methylation.36,37 In our study, a small proportion (9%) of the 679 
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CpGs differentially methylated between T- and B-lymphocytes were located within a 
bona fide CpG island (as defined by Takai and Jones26). Of interest however, 
approximately three-times as many CpGs (25.3%) resided within the associated CpG 
island shores, with a further 13.7% within island shelves. Thus, our data indicate that 
the majority of intrinsic differences in methylation between T-lymphocytes and B-
lymphocytes occur not within CpG islands per se but within the shores surrounding 
these islands (≤2 kb from the island). Of particular note, the importance of these CpG 
island “associated regions” in the context of gene expression has recently been 
described38 and is worthy of further investigation. Interestingly, analysis of global DNA 
methylation, using methylation of the LINE-1 retrotransposon as a surrogate measure, 
revealed marginal, yet statistically significant higher methylation in B-lymphocytes. To 
our knowledge this comparative increase has not previously been identified, and it is 
currently unclear as to its significance. 
 
Those genes identified as unmethylated in T-lymphocytes but hypermethylated in B-
lymphocytes included a significant number with known T-lymphocyte expression and 
functionality, such as ITK (a T-lymphocyte kinase), CD2 (early T-lymphocyte marker), 
and the genes for the delta, gamma and epsilon subunits of the CD3 T-cell co-receptor 
(CD3D, CD3G and CD3, respectively) which is expressed exclusively on T-
lymphocytes. Although not experimentally addressed in this study, our data suggest 
methylation-based epigenetic regulation of the CD3 locus, a finding that has recently 
been reported for leukocyte subsets.17 Analysis of functional enrichment by examining 
gene ontologies and pathways confirmed the predominance of genes associated with 
lymphocyte and leukocyte functioning amongst those differentially methylated between 
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the lymphocyte types. Similar enrichment of leukocyte/lymphocyte genes was 
previously reported by Reinius and colleagues,17 but in individual comparisons of each 
cell type with methylation in whole blood.  
 
In our investigation and for the purpose of defining intrinsic genome-wide differences in 
methylation between T-lymphocytes and B-lymphocytes, we adopted a stringent 
methodological approach. First, we isolated the individual cell populations using a 
validated technique that achieved mean purity in excess of 99% and 93% for each cell 
type respectively. Second, we implemented a series of stringent filtering criteria and 
independent validation to robustly identify those sites/genes displaying the most 
significant differences in methylation between the lymphocyte types. Finally, we only 
considered a gene to show altered methylation between the cell types if at least two 
CpGs from the same gene demonstrated statistically significant β-value differences ≥ 
0.2 and in the same direction (i.e. higher/lower in the same cell type), as used with 
success in a previous investigation from our laboratory.23 Independent validation of 19 
CpGs from eight selected candidate genes confirmed the large differences observed, and 
emphasizes the robustness of our data.  
 
Previous studies have reported subtle but significant differences in DNA methylation 
between tissue-types and between individuals,25 and additional reports provide evidence 
for associations of this epigenetic change with demographical factors such as age, 
gender and ethnicity,39,40 and lifestyle factors including smoking.41,42 Herein, and partly 
prompted by this literature, we focused our analyses on two lymphocyte populations in 
a carefully selected and closely matched, albeit small, cohort of healthy individuals 
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(Caucasian, non-smoking females, approximately 50-55 years of age). With regard to 
the limited variation in subject age, inspection of the results from hierarchical clustering 
revealed no evidence to suggest that younger and older individuals clustered separately. 
We are confident therefore, that our findings are not unduly influenced by potentially 
confounding variables such as those discussed above. 
 
The important issue of cellular heterogeneity as a confounder for DNA methylation 
analyses of blood-derived DNA has previously been recognised.16-18 Indeed, in the 
context of disease, underlying changes in the proportion of the different leukocyte 
populations may bias the identification of disease-specific changes in methylation. To 
address this issue a statistical algorithm has recently been described43 and provides an 
accurate method to estimate and adjust for leukocyte proportions in genome-wide DNA 
methylation studies.18,43 However, although this approach represents a significant 
advance, it is not able to determine the particular leukocyte populations in which 
disease-specific changes in DNA methylation occur. In these cases these changes 
represent an important question for diseases where different, specific, leukocyte 
populations play central roles in the disease process. In our own study, we have first set 
out to establish the intrinsic differences in methylation between matched pairs of 
purified T- and B-lymphocytes from healthy individuals. In this way we provide a 
foundation from which disease-specific changes of DNA methylation in these cell types 
may be determined.  
 
In summary, we have presented a unique genome-wide DNA methylation signature that 
accurately distinguishes healthy T-lymphocytes from B-lymphocytes. We recognize that 
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it will be important for future efforts to define methylation levels and disease-specific 
aberrations in these cell populations in RA patients, and to perhaps extend these types of 
analyses to individual cell subsets. The different T-helper subsets, for example, will be 
of particular interest given their distinct and multifaceted role in RA. 
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Patients and Methods 
Patients 
Peripheral blood samples (30 ml, EDTA) were collected from 10 healthy female 
Caucasians. Donors were recruited from the hospital staff population at the Haywood 
Rheumatology Centre, Stoke-on-Trent, and gave prior written informed consent. Each 
donor completed a short questionnaire to establish basic demographical information and 
to provide information on their current health status. The average age of the group was 
52.1 ± 5.0 years (mean ± SD) and none were current smokers. Individuals who reported 
any musculoskeletal or inflammatory-related conditions were excluded. The study was 
approved by the East Midlands (Derby) Research Ethics Committee.  
 
Isolation of individual lymphocyte populations 
Peripheral blood mononuclear cells were isolated from fresh whole blood samples by 
density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich). CD3+ T-
lymphocytes were purified from the mononuclear cell fraction using anti-CD3 magnetic 
microbeads, with subsequent isolation of CD19+ B-lymphocytes from the negative 
portion using anti-CD19+ magnetic microbeads (MiniMACS® separation system; 
Miltenyi Biotec). We chose to use positive selection as this has previously been 
demonstrated to be superior for array-based analyses of leukocytes44 and has minimal 
effects on leukocyte activation.45-48 All separations were performed according to the 
manufacturer’s instructions (Miltenyi Biotec). Cell preparations were immediately 
pelleted, lysed and homogenized (QIAShredder columns; Qiagen). Lysates were stored 
at –80°C. 
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Antibody staining and flow cytometry 
CD3+ T-lymphocytes and CD19+ B-lymphocytes from the ten donors were assessed for 
purity using flow cytometry. T-lymphocytes were stained with a murine phycoerythrin 
(PE)-labeled anti-CD3 IgG monoclonal antibody, and B-lymphocytes with a murine PE-
anti-CD20 IgG monoclonal antibody. Each sample was separately stained with the 
appropriate PE-labeled isotype-matched control antibody. Antibodies were purchased 
from Miltenyi Biotec. Samples were analyzed on a FACSort flow cytometer and raw 
data collected using CellQuest software (BD Biosciences). A forward scatter threshold 
of 180 was set and 10,000 events/sample were counted. Data were analyzed using 
Cyflogic software (version 1.2.1; CyFlo Ltd). Representative histograms of cell purity 
for each cell type are provided in Supplementary Figure 2. The mean ± SD purity for 
T-lymphocytes and B-lymphocytes from the ten donors was 99.6 ± 0.4% and 93.6 ± 
3.4%, respectively. 
 
Genome-wide DNA methylation analysis by Infinium 450K array 
Genomic DNA was extracted from thawed lysates using an AllPrep DNA/RNA Mini kit 
(Qiagen) according to the manufacturer’s instructions. Further purification and 
concentration of DNA was performed using ethanol-based precipitation reactions. DNA 
concentration was assessed using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific). 
 
Quantification of genome-wide DNA methylation was conducted using Infinium-based 
HumanMethylation450 BeadChips. Each array enables simultaneous quantification of 
methylation at 485,577 unique CpGs across the genome, representing 21,231 RefSeq 
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genes (99% coverage), in 12 independent samples in parallel.49 Array hybridizations 
were performed by Gen-Probe Life Sciences Ltd (Manchester, UK) according to 
Illumina recommended protocols. Briefly, 650 ng of genomic DNA was sodium 
bisulfite converted using an EZ DNA Methylation Kit (Zymo Research). Subsequently, 
4 µl of bisulfite-converted DNA was hybridized to 450K arrays following the Illumina 
Infinium HD Methylation protocol. Each sample was arrayed once. Arrays were 
scanned using an Illumina iScan and image intensities extracted using the 
GenomeStudio Methylation Module (version 1.8.5). The methylation status of each 
CpG/probe was reported as a methylation β-value, where β is defined as the ratio of the 
methylated signal intensity over the summed intensity of the methylated and 
unmethylated signals + 100.49 β-values were reported on a continuous linear scale 
ranging from 0 (unmethylated) to 1 (completely methylated). 
 
Whole genome amplification and touchdown PCR 
Sodium bisulfite-converted DNA samples used on the arrays were separately used for 
validation of array data and to confirm the methylation status of identified candidate 
CpGs/genes. To increase template quantity, samples were first subjected to whole 
genome amplification according to a protocol described by Mill et al.50 Briefly, 1 µl 
bisulfite-converted DNA was amplified by polymerase chain reaction (PCR) using 
GoTaq Flexi DNA polymerase and buffer (Promega), dNTPs (Bioline) and random 15-
mer oligonucleotide primers (200 pmoles; Life Technologies). Thermal cycling 
conditions were: 98°C for 3 minutes, followed by 50 cycles of 98°C for 1 minute, 37°C 
for 2 minutes and 55°C for 4 minutes, with a ramping rate of 0.1°C/second prior to each 
denaturation and extension step. 
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PCR amplicons that encompassed CpGs of interest were generated from whole genome 
amplified DNA using touchdown PCR.51,52 Forward, reverse and sequencing primers 
specific for bisulfite-converted DNA were designed using PyroMark Assay Design 
software (version 2.0; Qiagen) and were purchased from Biomers.net (primer sequences 
are provided in Supplementary Table 2). In each 25 µl PCR reaction, 2-4 µl whole 
genome-amplified DNA was amplified with the appropriate forward and reverse 
primers, as we have described previously.53  
 
Validation by sodium bisulfite Pyrosequencing 
Methylation at individual CpG sites was quantified by Pyrosequencing of bisulfite-
converted PCR-amplified DNA using a PyroMark Q24 instrument (Qiagen). 
Pyrosequencing was performed according to the manufacturer’s instructions and as we 
have previously described.23,53 The sequence to analyze for each CpG/gene is provided 
in Supplementary Table 2 and all assays included one or more control dispensations to 
confirm sequence identity and completeness of bisulfite conversion. Data were analyzed 
using PyroMark Q24 software (v 2.0.6., build 20; Qiagen). 
 
Data analysis 
Array data were analyzed using NIMBL software.54 Each array passed initial quality 
control assessment based on the performance of internal array controls, and the 
distribution of β-values across all 485,577 CpGs was found to be similar in each 
sample. All CpGs for which one or more of the 20 samples displayed detection p-values 
> 0.05 (indicating an unreliable site) or presented with missing β-values were excluded. 
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As we have described previously, we considered it a more robust approach to remove 
from the dataset CpGs that failed in any one of the samples rather than excluding 
individual failed CpGs from specific samples.24 To adjust for the observation that β-
values derived from Infinium II probes on the 450K array can be less sensitive than 
those generated from Infinium I probes, NIMBL was used to perform ‘peak-based 
correction’ as devised by Dedeurwaerder et al.55 
 
Criteria for identification of differentially methylated CpGs are described in detail in the 
Results. Statistical analysis of DNA methylation at individual CpG sites was compared 
between T-lymphocytes and B-lymphocytes using paired t-tests. Correction for multiple 
testing was performed using the false discovery rate (FDR) adjustment of Benjamini 
and Hochberg,29 with adjusted p-values < 0.05 considered significant. Euclidian-based 
hierarchical clustering of differentially methylated CpGs was performed using Genesis 
software (v1.7.6).56 Differentially methylated genes were assessed for enrichment of 
gene ontology terms and biological pathways using DAVID online software.27,28 
Additional statistical analyses were performed using NCSS 2000 (NCSS LCC). P-
values < 0.05 were considered significant. 
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Figure legends 
Figure 1. Technical validation of 450k array data by sodium bisulfite 
Pyrosequencing. Correlation of DNA methylation as measured by array β-value and by 
bisulfite Pyrosequencing for 70 individual sites in T-lymphocytes and B-lymphocytes 
from seven of the ten healthy individuals (5 CpGs were selected at random, from three 
separate genes: HMOX2: cg14951292, AMN: cg09616556, PM20D1: cg24503407, 
cg07167872, cg11965913). T- and B-lymphocytes are shown as circles and crosses, 
respectively. Spearman’s r = 0.952, p < 0.00001. 
 
Figure 2. LINE-1 DNA methylation in matched pairs of T-lymphocytes and B-
lymphocytes. Sodium bisulfite Pyrosequencing was used to quantify methylation at 
three CpG sites within LINE-1 repetitive sequences in purified T-lymphocytes and B-
lymphocytes from ten healthy individuals. T- and B-lymphocytes are shown as circles 
and crosses, respectively. The mean level of methylation for each CpG site in each cell 
population is shown by the short black horizontal bar in each case.  
* p ≤ 0.01 (Wilcoxon Signed-Rank Test). 
 
Figure 3. Criteria for filtering and identification of CpGs differentially methylated 
between paired T-lymphocyte and B-lymphocyte samples. The starting number of 
484,616 CpGs was derived through removal of CpGs with high detection p-values (p > 
0.05) and those with missing β-values, as described in the Methods. 
† ‘Change’ refers to a methylation difference which fulfilled all preceding filtering 
steps. 
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‡ ‘Change in the same direction’ refers to multiple CpGs from one gene all showing 
either hyper- or hypomethylation in one cell type as compared with the other cell type. 
 
Figure 4. Heatmap and clustering for the 679 CpGs identified as differentially 
methylated. CpG sites identified by 450K array analysis as differentially methylated 
between paired T-lymphocytes (green bar) and B-lymphocytes (red bar) were analyzed 
by hierarchical clustering. Each row represents an individual CpG site and each column 
a different sample (listed beneath the heatmap). Branches of the dendrograms indicate 
similarity between CpGs (rows) and samples (columns). Color gradation from yellow to 
blue represents low to high DNA methylation respectively, with β-values ranging from 
0 (no methylation; yellow) to 1 (complete methylation; blue). Sample order, left-to-
right: B-lymphocytes: HC03, 10, 04, 09, 11, 14, 08, 12, 16, 17;  and T-lymphocytes: 
HC03, 08, 09, 11, 12, 04, 14, 16, 10, 17. 
 
Figure 5. Validation of differentially methylated CpG candidates identified by 
450K array analysis. Sodium bisulfite Pyrosequencing was used to confirm candidate 
genes/CpGs that were differentially methylated between T-lymphocytes and B-
lymphocytes in all ten healthy individuals. CpG sites in four genes that were 
hypermethylated in T-lymphocytes (A) and four genes that were hypermethylated in B-
lymphocytes (B) were selected from the array candidates. T- and B-lymphocytes are 
shown by circles and crosses, respectively. Gene names are shown on the x-axis, where 
for each gene methylation values are shown for the array (left) and Pyrosequencing 
(right). The mean values are defined by the horizontal black bar in each case. The 
methylation differences observed between T-lymphocytes and B-lymphocytes by 
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Pyrosequencing analysis were statistically significant for each of the eight CpGs/genes 
examined (p < 0.01, Wilcoxon Signed-Rank Test). 
Abbreviations: Pyro., bisulfite Pyrosequencing. 
 
Figure 6. Representative plots displaying validation of multiple array CpGs within 
two candidate genes by sodium bisulfite Pyrosequencing analysis. Four CpGs within 
the RNH1 gene (A) and three within PITPNC1 (B), all of which demonstrated 
significant differences in methylation between T-lymphocytes and B-lymphocytes by 
array analysis, were examined. T- and B-lymphocytes are shown as circles and crosses, 
respectively. CpG identifiers are shown on the x-axis (in each case, the first site shown 
for RNH1 (A) and PITPNC1 (B) is the site depicted in Figure 5A and 5B, respectively). 
For each site, methylation values are shown for the array (left) and Pyrosequencing 
(right). The mean values are defined by the horizontal black bar in each case. The CpG 
sites are displayed in the 5’ to 3’ direction, with the four sites in RNH1 covering 20-bp 
and three sites in PITPNC1 covering 45-bp. The methylation differences observed 
between T-lymphocytes and B-lymphocytes by Pyrosequencing analysis were 
statistically significant for each of the CpGs in each gene examined (p < 0.01, Wilcoxon 
Signed-Rank Test). 
Abbreviations: Pyro., bisulfite Pyrosequencing. 
 
Supplementary Figure 1. Heatmap and clustering for the 2,306 CpGs identified as 
differentially methylated. Sites on the 450K array were identified as differentially 
methylated between paired T-lymphocyte (green bar) and B-lymphocyte (red bar) 
samples at step 3 of the filtering flow diagram. Each row represents an individual CpG 
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site and each column a different sample (listed beneath the heatmap). Branches of the 
dendrograms indicate similarity between CpGs (rows) and samples (columns). Color 
gradation from yellow to blue represents low to high DNA methylation respectively, 
with β-values ranging from 0 (no methylation; yellow) to 1 (complete methylation; 
blue). Sample order, left-to-right: B-lymphocytes: HC03, 10, 04, 09, 11, 14, 08, 12, 16, 
17;  and T-lymphocytes: HC03, 08, 09, 11, 10, 12, 04, 14, 16, 17. 
 
Supplementary Figure 2. Representative flow cytometry histograms depicting cell 
purity for the T-lymphocyte and B-lymphocyte isolation procedures. The purity of 
each T-lymphocyte and B-lymphocyte isolation procedure was assessed quantitatively 
by flow cytometry. Shown for each of three healthy individuals – HC08 (red trace), 
HC12 (blue trace) and HC16 (green trace) – are cell purity histograms for the T-
lymphocyte (A) and B-lymphocyte (B) isolations. Representative isotype-matched 
control data (HC12) is shown by the black trace with grey fill, where the horizontal 
bracket indicates background staining for 95% of the isotype control which was used as 
the threshold to determine CD3/CD20 positive staining. T-lymphocytes were stained 
with a murine PE-labeled anti-CD3 IgG monoclonal antibody, and B-lymphocytes with 
a murine PE-anti-CD20 IgG monoclonal antibody. The overall mean ± SD purity for the 
study cohort (n = 10) was 99.6 ± 0.4% and 93.6 ± 3.4% for T-lymphocytes and B-
lymphocytes, respectively. 
 
Supplementary Table 1. 450K array β-value matrix and accompanying 
calculations for the 679 CpGs identified as differentially methylated between T-
lymphocytes and B-lymphocytes. 
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*Unless otherwise stated, values in the data matrix are methylation array β-values. The 
solid black horizontal line at row 522 separates CpGs hypermethylated in B-
lymphocytes (above) from those hypermethylated in T-lymphocytes (below). 
† FDR, false discovery rate adjustment for multiple comparisons.29 
 
Supplementary Table 2. List of genes, associated CpGs and primer sequences 
interrogated by bisulfite Pyrosequencing. 
*Further information that is not included here is available upon request. The horizontal 
dashed line at row 10 separates candidate genes hypermethylated in T-lymphocytes 
(above) and hypermethylated in B-lymphocytes (below). 
†The prefix 'b-' denotes biotin labeling at the 5' end of the primer. 
‡The sequence indicated is post-bisulfite conversion and the letters 'Y' and 'R' denote 
the cytosine of interrogated CpG sites ('Y' and 'R' refer to sequencing along the upper 
and lower strands respectively). 
Abbreviations: bp, base pairs  
 
Supplementary Table 3. Gene ontology categories identified by analysis using 
DAVID as significantly enriched in the 250 genes differentially methylated 
between T-lymphocytes and B-lymphocytes. 
*DAVID, Database for Annotation, Visualization and Integrated Discovery.27,28 Data 
shown are the output from running the Functional Annotation Chart tool on the three 
parent gene ontology domains (Biological Process, Cellular Component and Molecular 
Function) and all sub-categories contained within. Listed are all ontologies that were 
statistically significant at the p < 0.05 level using the EASE score.27,28 The solid black 
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horizontal line at row 34 indicates the cut-off for enriched ontology terms that remained 
statistically significant following adjustment for multiple comparisons using the FDR 
method (False Discovery Rate29). 
†Gene ontology terms listed belong to the parent ontology indicated, where BP, CC and 
MF indicate biological process, cellular component and molecular function, 
respectively. 
‡P-values are calculated from the EASE score, a modified version of Fisher's Exact 
Test.27,28 
 
Supplementary Table 4. Clustering using DAVID of similar gene ontology 
annotation terms, based on common membership of enriched genes, identified in 
the 250 genes differentially methylated between T-lymphocytes and B-
lymphocytes. 
*DAVID, Database for Annotation, Visualization and Integrated Discovery.27,28 Data 
shown are the output from running the Functional Annotation Chart tool on the three 
parent gene ontology domains (Biological Process, Cellular Component and Molecular 
Function) and all sub-categories contained within. Listed are all ontologies statistically 
significant at the p < 0.05 level using the EASE score.27,28 The solid black horizontal 
line at row 58 indicates the cut-off for clusters containing enriched ontology terms of 
which at least half remained statistically significant following adjustment for multiple 
comparisons using the FDR method (False Discovery Rate29).  
†Gene ontology terms listed belong to the parent ontology indicated, where BP, CC and 
MF indicate biological process, cellular component and molecular function, 
respectively. 
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‡P-values are calculated from the EASE score, a modified version of Fisher's Exact 
Test.27,28 
 
Supplementary Table 5. Pathways identified by analysis using DAVID as 
significantly enriched in the 250 genes differentially methylated between T-
lymphocytes and B-lymphocytes. 
*DAVID, Database for Annotation, Visualization and Integrated Discovery.27,28 Data 
shown are the output from running the Functional Annotation Chart tool on selected 
pathway databases. Listed are all pathways that were statistically significant at the p < 
0.05 level using the EASE score.27,28 The solid black horizontal line at row 13 indicates 
the cut-off for enriched pathways that remained statistically significant following 
adjustment for multiple comparisons using the FDR method (False Discovery Rate29). 
†Pathways listed are from the KEGG30-32, Biocarta and PANTHER33 databases, as 
indicated. 
‡P-values are calculated from the EASE score, a modified version of Fisher's Exact 
Test.27,28 
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Table 1. Summary characteristics of the 679 CpGs identified as differentially methylated between paired T-lymphocyte and B-lymphocyte 
samples by genome-wide DNA methylation analysis using 450K arrays.* 
 Hypermethylated in 
T-lymphocytes 
Hypermethylated in 
B-lymphocytes  
All differentially 
methylated CpGs 
CpGs differentially methylated† 159 (23.4) 520 (76.6) 679 (100) 
     In CpG islands 27 (17.0) 34 (6.5) 61 (9.0) 
     In CpG island shores 60 (37.7) 112 (21.5) 172 (25.3) 
     In CpG island shelves 14 (8.8) 79 (15.2) 93 (13.7) 
     Non-island CpGs 58 (36.5) 295 (56.7) 353 (52.0) 
Maximum β-value difference‡ 0.712 0.864 0.864 
CpGs with β-value difference ≥ 0.5 22 (13.8) 304 (58.5) 326 (48.0) 
Genes represented 67 183 250 
Maximum number of CpGs in a gene§ 6 18 18 
 
Unless otherwise indicated, all figures are the number (%). 
*Differentially methylated CpGs were identified according to the criteria described in the Results section and Figure 3. 
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†Annotation describing CpG island, shore and shelf status is derived from the University of California at Santa Cruz (UCSC) database. A 
significant association between cell type and the distribution of CpGs according to CpG island status was observed (p < 0.00001, Chi-
squared test).  
‡Maximum β-value difference refers to the largest mean difference in β-value observed for any single CpG between T-lymphocytes and B-
lymphocytes (mean value calculated from ten pairwise comparisons). 
§Refers to the maximum number of differentially methylated CpGs identified within a single gene. 
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Table 2. Annotation for the top 10 hypermethylated genes in T-lymphocytes and top 10 hypermethylated genes in B-lymphocytes, as 
determined by genome-wide DNA methylation analysis.* 
Gene symbol† 
CpGs 
differentially 
methylated 
Mean (range) 
β-value difference‡ 
Gene name† Functional summary† 
     
Hypermethylated in T-lymphocytes   
CTSZ 3 0.612  (0.55 - 0.70) Cathepsin Z Lysosomal cysteine proteinase 
RNF11 2 0.586  (0.56 - 0.61) Ring finger protein 11 Protein-protein interactions 
PIK3R2 2 0.576  (0.55 - 0.60) Phosphoinositide-3-kinase, 
regulatory subunit 2 (beta) 
Lipid kinase, growth signaling pathways 
 
FGR 3 0.566  (0.46 - 0.71) Feline Gardner-Rasheed sarcoma 
viral oncogene homolog 
Protein tyrosine kinase, cell migration and 
adhesion 
ELMO1 2 0.533  (0.50 - 0.57) Engulfment and cell motility 1 Phagocytosis and cell migration 
LYL1 2 0.519  (0.47 - 0.57) Lymphoblastic leukemia derived Transcription factor, blood vessel 
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sequence 1 maturation and hematopoiesis 
WIPI2 5 0.504  (0.33 - 0.71) WD repeat domain, 
phosphoinositide  interacting 2 
WD40 repeat protein, multiprotein complex 
assembly 
CD82 2 0.481  (0.46 - 0.50) CD82 molecule Transmembrane 4 superfamily glycoprotein 
LRP5 2 0.470  (0.27 - 0.67) Low density lipoprotein receptor-
related protein 5 
Lipoprotein receptor, skeletal homeostasis 
CLPTM1L 2 0.465  (0.46 - 0.47) CLPTM1-like Anti-apoptotic, lung cancer 
     
Hypermethylated in B-lymphocytes   
SPATA13 2 0.814  (0.79 - 0.84) Spermatogenesis associated 13 Guanine nucleotide exchange factor, cell 
migration and adhesion assembly 
CD3D 4 0.808  (0.76 - 0.85) CD3d molecule, delta (CD3-TCR 
complex) 
T-cell co-receptor, T-cell receptor signalling 
TNRC6B 3 0.788  (0.74 - 0.82) Trinucleotide repeat containing 6B RNA-mediated gene silencing 
CD3G 5 0.783  (0.75 - 0.85) CD3g molecule, gamma (CD3- T-cell co-receptor, T-cell receptor signaling 
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TCR complex) 
UBASH3A 7 0.775  (0.69 - 0.83) Ubiquitin associated and SH3 
domain containing A 
T-cell ubiquitin ligand, T-cell signaling 
FYB 4 0.767  (0.68 - 0.84) FYN binding protein T-cell adapter protein, IL-2 expression 
MGAT4A 3 0.756  (0.72 - 0.82) Mannosyl (alpha-1,3-)-
glycoprotein beta-1, 4-N-
acetylglucosaminyltransferase, 
isozyme A 
Glycosyltransferase, Golgi structural 
branching 
PLCG1 2 0.745  (0.69 - 0.80) Phospholipase C, gamma 1 Intracellular transduction of receptor-
mediated tyrosine kinase activators 
EXOC1 2 0.743  (0.69 - 0.79) Exocyst complex component 1 Exocytic vesicle targeting, cytoskeletal 
remodeling 
MPHOSPH9 2 0.734  (0.72 - 0.74) M-phase phosphoprotein 9 Cell cycle 
 
*Differentially methylated CpGs were identified according to the criteria described in the Results section and Figure 3. 
†The official gene symbol, gene name and stated function were retrieved from the NCBI Gene database (accessed May 2013). 
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‡The mean β-value difference was calculated as the average of the individual β-value differences determined for each differentially 
methylated CpG within the indicated gene (the difference for each individual CpG was calculated as described in the Results). 
 
